|
May 12
|
AB Science reports its revenues for the year 2024 and provides an update on its activities
|
|
May 5
|
AB Science will present new data from masitinib clinical program in ALS in two presentations at the 2025 ENCALS Annual Meeting
|
|
May 1
|
AB Science will publish its 2024 annual financial report on May 9, 2025
|
|
Apr 14
|
AB Science receives notice of allowance for Unites States patent covering masitinib until 2040 in the treatment of sickle cell disease
|
|
Oct 10
|
AB Science: Revenues for the first half of 2024 and update on AB Science’s activities
|
|
May 7
|
AB Science : A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patient
|
|
Jan 15
|
AB Science receives notice of allowance for European patent covering masitinib until 2036 in the treatment of mastocytosis
|
|
Nov 28
|
AB Science will host a live webcast on Thursday November 30, 2023, from 3pm to 4pm CET, to present the masitinib development program in sickle cell disease
|
|
Nov 27
|
AB Science: The clinical development of masitinib in sickle cell disease is among the 19 winning projects under the sixth call for “Hospital-Inuversity Research in health (RHU)”
|